ADULTS with moderate-to-severe plaque psoriasis treated with the oral interleukin-23 (IL-23) receptor inhibitor icotrokinra maintained high rates of skin clearance and symptom improvement through 52 weeks, according to new Phase III data from the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials.
The one-year findings build on previously reported results showing that once-daily icotrokinra achieved significantly greater skin clearance than both placebo and deucravacitinib during the first 24 weeks of treatment. The latest analysis evaluated the durability of response and long-term safety in 1,505 adults with moderate-to-severe plaque psoriasis.
Participants were randomised to receive icotrokinra 200 mg once daily, placebo with crossover to icotrokinra at Week 16, or deucravacitinib 6 mg once daily with crossover to icotrokinra at Week 24. Efficacy was assessed using Investigator’s Global Assessment (IGA), Psoriasis Area and Severity Index (PASI), scalp-specific IGA, and multiple patient-reported outcome measures.
One-Year Efficacy Remains Durable
Among participants initially assigned to icotrokinra, skin clearance rates continued to improve through Week 24 and were maintained to Week 52. Approximately 70–75% achieved clear or almost clear skin, as measured by IGA 0/1 and PASI 90, while around half achieved complete skin clearance, meeting IGA 0 or PASI 100 criteria.
Durability of response was also notable. Among patients who achieved clear or almost clear skin by Week 16, approximately 85–90% maintained this level of disease control through one year.
Switching to Icotrokinra Improves Outcomes
Participants who crossed over from placebo or deucravacitinib to icotrokinra demonstrated steadily increasing response rates after switching, with outcomes comparable to those observed in participants who received icotrokinra from the start of the study by Week 52.
Patient-reported outcomes also remained favourable throughout the study. Improvements in itch, psoriasis symptoms, quality of life, and scalp disease were sustained over one year.
The safety profile remained consistent with earlier findings. Adverse event rates were similar to placebo during the placebo-controlled period and lower than those reported with deucravacitinib during the active-comparator phase. No new safety signals emerged through 52 weeks.
The investigators concluded that once-daily icotrokinra provided robust and durable disease control with sustained improvements in both clinical and patient-reported outcomes. They suggest these findings support the oral IL-23 receptor inhibitor as a potential long-term systemic treatment option for adults with moderate-to-severe plaque psoriasis.
Reference
Gold LS et al. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: one-year results from the phase 3, placebo- and active comparator-controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 trials. Br J Dermatol. 2026;DOI: 10.1093/bjd/ljag264.
Featured image: Ольга Тернавская on Adobe Stock
- Author:
